{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:00:12Z","timestamp":1776722412966,"version":"3.51.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aims:<\/jats:bold> This study aimed to develop a population pharmacokinetic (PopPK) model of ilaprazole in healthy subjects and patients with duodenal ulcer in Chinese and investigate the effect of potential covariates on pharmacokinetic (PK) parameters.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Pharmacokinetic data from 4 phase I clinical trials and 1 phase IIa clinical trial of ilaprazole were included in PopPK analysis. Phoenix NLME 8.3 was used to establish a PopPK model and quantify the effects of covariate, such as demographic data, biochemical indicators and disease state on the PK parameters of ilaprazole. The final model was evaluated by goodness-of-fit plots, bootstrap analysis, and visual predictive check.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A two-compartment model with first-order elimination successfully described the pharmacokinetic properties of ilaprazole. In the final PopPK model, body weight and sex were identified as statistically significant covariates for volume of peripheral compartment (V<jats:sub>p<\/jats:sub>) and clearance of central compartment (CL), respectively, and disease status was also screened as a significant covariate affecting both CL and V<jats:sub>p<\/jats:sub>. The validation results demonstrated the good predictability of the model, which was accurate and reliable.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This is the first population pharmacokinetics study of ilaprazole in the Chinese, and the PopPK model developed in this study is expected to be helpful in providing relevant PK parameters and covariates information for further studies of ilaprazole.<\/jats:p>","DOI":"10.3389\/fphar.2023.1306222","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T04:12:02Z","timestamp":1704859922000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China"],"prefix":"10.3389","volume":"14","author":[{"given":"Mengyang","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shupeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/17425255.2022.2098107","article-title":"An update on drug-drug interactions associated with proton pump inhibitors","volume":"18","author":"Ben Ghezala","year":"2022","journal-title":"Expert Opin. drug metabolism Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.11648\/J.AJLS.S.2015030104.13","article-title":"Gender, but not CYP2C19 genotypes and CYP3A phenotypes, is a major determinant of ilaprazole pharmacokinetic","volume":"3","author":"Cao","year":"2015","journal-title":"Am. J. Life Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/17512433.2022.2075343","article-title":"Population pharmacokinetics of omeprazole in obese and normal-weight adults","volume":"15","author":"Chen","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1177\/0091270011408611","article-title":"Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole","volume":"52","author":"Cho","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"B6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/MCG.0000000000001186","article-title":"Ilaprazole compared with rabeprazole in the treatment of duodenal ulcer: a randomized, double-blind, active-controlled, multicenter study","volume":"53","author":"Fan","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF03190260","article-title":"Gender differences in pharmacokinetics","volume":"21","author":"Gleiter","year":"1996","journal-title":"Eur. J. drug metabolism Pharmacokinet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jcph.1650","article-title":"Nonparametric methods in population pharmacokinetics","volume":"62","author":"Goutelle","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021","volume":"57","author":"Iwakiri","year":"2022","journal-title":"J. gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"120042","DOI":"10.1016\/j.lfs.2021.120042","article-title":"An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties","volume":"286","author":"Jiang","year":"2021","journal-title":"Life Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0021-9681(72)90027-6","article-title":"Indices of relative weight and obesity","volume":"25","author":"Keys","year":"1972","journal-title":"J. chronic Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1055\/s-0031-1300002","article-title":"General pharmacology of IY-81149, a new proton pump inhibitor","volume":"51","author":"Kim","year":"2001","journal-title":"Arzneim."},{"key":"B14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1055\/s-0031-1300026","article-title":"Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo","volume":"51","author":"Kwon","year":"2001","journal-title":"Arzneim."},{"key":"B15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/17425255.2011.570331","article-title":"The effects of obesity on drug pharmacokinetics in humans","volume":"7","author":"Morrish","year":"2011","journal-title":"Expert Opin. drug metabolism Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/jcpt.13129","article-title":"Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes","volume":"45","author":"Nagase","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1248\/bpb.30.2238","article-title":"Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males","volume":"30","author":"Sakurai","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"B19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/00498254.2011.622416","article-title":"Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5","volume":"42","author":"Seo","year":"2012","journal-title":"Xenobiotica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejpb.2020.01.015","article-title":"The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors","volume":"149","author":"Shen","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/apt.12860","article-title":"The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study","volume":"40","author":"Shin","year":"2014","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical significance","volume":"24","author":"Tanaka","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40261-016-0390-2","article-title":"Pharmacokinetics, pharmacodynamics and safety of multiple-infusion ilaprazole in healthy Chinese subjects","volume":"36","author":"Wang","year":"2016","journal-title":"Clin. drug Investig."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3109\/00498254.2016.1156185","article-title":"Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1111\/bcp.14076","article-title":"Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control","volume":"85","author":"Wang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1185\/03007995.2011.639353","article-title":"Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial","volume":"28","author":"Wang","year":"2012","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1306222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T04:12:05Z","timestamp":1704859925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1306222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":27,"alternative-id":["10.3389\/fphar.2023.1306222"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1306222","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"article-number":"1306222"}}